TIGIT Human
Sf9, Baculovirus cells.
VSIG9, VSTM3, WUCAM, V-set and immunoglobulin domain-containing protein 9, V-set and transmembrane domain-containing protein 3.
Greater than 90.0% as determined by SDS-PAGE.
Description
TIGIT produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 359 amino acids (22-141a.a.) and having a molecular mass of 40.0kDa. (Molecular size on SDS-PAGE will appear at approximately 40-57kDa).
TIGIT is expressed with a 239 amino acid hlgG-His tag at C-Terminus and purified by proprietary chromatographic techniques.
Product Specs
VSIG9, VSTM3, WUCAM, V-set and immunoglobulin domain-containing protein 9, V-set and transmembrane domain-containing protein 3.
Sf9, Baculovirus cells.
MMTGTIETTG NISAEKGGSI ILQCHLSSTT AQVTQVNWEQ QDQLLAICNA DLGWHISPSF KDRVAPGPGL GLTLQSLTVN DTGEYFCIYH TYPDGTYTGR IFLEVLESSV AEHGARFQIP LEPKSCDKTH TCPPCPAPEL LGGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS RDELTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGKHHHHHH.
Product Science Overview
T-Cell Immunoreceptor With Ig And ITIM Domains (TIGIT) is a co-inhibitory receptor expressed on various immune cells, including activated T cells, memory T cells, regulatory T cells (Tregs), and natural killer (NK) cells . TIGIT plays a crucial role in regulating immune responses, particularly in the context of cancer and infectious diseases .
TIGIT is a transmembrane glycoprotein receptor that contains an immunoglobulin-like V-type domain in its extracellular region and an immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic domain . The receptor primarily binds to its high-affinity ligand CD155 (also known as PVR) and, to a lesser extent, to CD112 (PVRL2) . The interaction between TIGIT and its ligands leads to the inhibition of T-cell and NK cell functions, thereby modulating immune responses .
TIGIT has been identified as a significant immune checkpoint that promotes tumor cell immune evasion by inhibiting T-cell and NK cell cytotoxicity . Overexpression of TIGIT has been observed in various malignancies and is associated with cancer progression, distant metastases, and poor patient prognosis . Blocking TIGIT with monoclonal antibodies, especially in combination with programmed cell death protein 1 (PD-1) blockade, has shown promise in preventing tumor progression, metastasis, and recurrence in preclinical models .
The inhibition of TIGIT is currently being evaluated in clinical trials, particularly in combination with other immune checkpoint inhibitors . Early results from these trials suggest that targeting TIGIT, along with PD-1 or PD-L1 blockade, may enhance anti-tumor immune responses and improve clinical outcomes in patients with solid tumors .
